Outcomes based on risk-adapted adjuvant therapy in postmenopausal women with early breast cancer: a nationwide, prospective cohort study by the Danish Breast Cancer Group

Breast Cancer

Body mass index as a predictive factor for efficacy of adjuvant taxane-based chemotherapy in early-stage breast cancer patients: A pooled analysis from adjuvant GEICAM Spanish Breast Cancer Group and TRIO Translational Research in Oncology Group studies

Int J Cancer

García-Saenz JA, Spera G, Pollán M, Bermejo B, Ruiz-Borrego M, Chan A, Martín M, Guerrero-Zotano Á, Calvo L, Rodríguez-Lescure Á, Marín M, Chap L, Crown J, Pienkowski T, Bee V, Casas M, Polonio Ó, Bezares S, Slamon D

doi: 10.1002/ijc.35432

Breast Cancer

Prospective study on Oncotype DX® assay to assess recurrence risk in early ER-positive HER2-negative breast cancer patients with uncertain biological behavior by standard parameters and its impact on treatment recommendation: The POST trial

Eur J Cancer

Livraghi L, Martella F, Ghilli M, Angiolini C, Magnanini S, Moretti E, Bengala C, Risi E, Molinara E, Pazzagli I, Malorni L, Donati S, Gabellini S, Martignetti A, Giannessi P, Sanna G, Barellini L, Biagioni C, Boni L, Bianchi S, Roncella M, Biganzoli L

doi: 10.1016/j.ejca.2024.115108

Breast Cancer

Breast Cancer Index in Premenopausal Women With Early-Stage Hormone Receptor-Positive Breast Cancer

JAMA Oncol

O'Regan RM, Zhang Y, Fleming GF, Francis PA, Kammler R, Viale G, Dell'Orto P, Lang I, Bellet M, Bonnefoi HR, Tondini C, Villa F, Bernardo A, Ciruelos EM, Neven P, Karlsson P, Müller B, Jochum W, Zaman K, Martino S, Geyer CE Jr, Jerzak KJ, Davidson NE, Coleman RE, Ingle JN, van Mackelenbergh MT, Loi S, Colleoni M, Schnabel CA, Treuner K, Regan MM

doi: 10.1001/jamaoncol.2024.3044

RECOMMENDED

Breast Cancer

Single-modality endocrine therapy versus radiotherapy after breast-conserving surgery in women aged 70 years and older with luminal A-like early breast cancer (EUROPA): a preplanned interim analysis of a phase 3, non-inferiority, randomised trial

★ 3 Recommended by Dr Andreas Müller, Faculty Member

Lancet Oncol

Meattini I, De Santis MC, Visani L, Scorsetti M, Fozza A, Meduri B, De Rose F, Bonzano E, Prisco A, Masiello V, La Rocca E, Spoto R, Becherini C, Blandino G, Moscetti L, Colciago RR, Audisio RA, Brain E, Caini S, Hamaker M, Kaidar-Person O, Lambertini M, Marrazzo L, Saieva C, Spanic T, Strnad V, Wheelwright S, Poortmans PMP, Livi L, EUROPA Trial Investigators

doi: 10.1016/S1470-2045(24)00661-2

Breast Cancer

Tailored Dose-Dense Versus Standard Adjuvant Chemotherapy for High-Risk Early Breast Cancer: End-of-Study Results of the Randomized PANTHER Trial

J Clin Oncol

Matikas A, Möbus V, Greil R, Andersson A, Steger GG, Untch M, Fornander T, Malmström P, Schmatloch S, Johansson H, Hellström M, Brandberg Y, Gnant M, Loibl S, Foukakis T, Bergh J, SweBCG, ABCSG and GBG

doi: 10.1200/JCO.24.00178

Lung, Respiratory and Thoracic Cancer

Long-term outcome of chemoimmunotherapy for extensive-stage small-cell lung cancer according to key clinical trial eligibility: 3-year outcomes from a prospective cohort study

Lung Cancer

Sugisaka J, Fujimoto D, Tamiya M, Hata A, Matsumoto H, Yokoyama T, Taniguchi Y, Uchida J, Sato Y, Kijima T, Tanaka H, Furuya N, Masuda T, Sakata Y, Miyauchi E, Saito G, Miura S, Yamaguchi T, Daga H, Sakata S, Yamamoto N, Akamatsu H

doi: 10.1016/j.lungcan.2024.108056

RECOMMENDED

Breast Cancer

Endocrine therapy and risk of cardiovascular disease and mortality in postmenopausal breast cancer survivors

★ 3 Recommended by Prof. Dr Beat Thürlimann, Faculty Member

J Natl Cancer Inst

Huang Y, Kwan ML, Heckbert SR, Smith NL, Othus M, Laurent CA, Roh JM, Rillamas-Sun E, Lee VS, Kolevska T, Cheng RK, Irribarren C, Nguyen-Huynh M, Hershman DL, Kushi LH, Greenlee H

doi: 10.1093/jnci/djaf063

Gastrointestinal Cancer

Real-world treatment patterns and outcomes based on RAS/BRAF status in metastatic colorectal cancer-Analysis of the Prospective Dutch Colorectal Cancer cohort

Int J Cancer

van Nassau SCMW, Zwart K, van der Baan FH, Vink GR, Elferink MAG, Snaebjornsson P, May AM, Koopman M, Roodhart JML

doi: 10.1002/ijc.35410

Breast Cancer

Factors influencing 5-year persistence to adjuvant endocrine therapy in young women with breast cancer

Breast

Pagan E, Ruggeri M, Bianco N, Bucci EO, Graffeo R, Borner M, Giordano M, Gianni L, Rabaglio M, Freschi A, Cretella E, Seles E, Farolfi A, Simoncini E, Ciccarese M, Rauch D, Favaretto A, Honecker F, Berardi R, Franzetti-Pellanda A, Gelber S, Partridge AH, Goldhirsch A, Bagnardi V, Pagani O, Ribi K

doi: 10.1016/j.breast.2024.103765

Related content

Body mass index as a predictive factor for efficacy of adjuvant taxane-based chemotherapy in early-stage breast cancer patients: A pooled analysis from adjuvant GEICAM Spanish Breast Cancer Group and TRIO Translational Research in Oncology Group studies

Prospective study on Oncotype DX® assay to assess recurrence risk in early ER-positive HER2-negative breast cancer patients with uncertain biological behavior by standard parameters and its impact on treatment recommendation: The POST trial

Breast Cancer Index in Premenopausal Women With Early-Stage Hormone Receptor-Positive Breast Cancer

Single-modality endocrine therapy versus radiotherapy after breast-conserving surgery in women aged 70 years and older with luminal A-like early breast cancer (EUROPA): a preplanned interim analysis of a phase 3, non-inferiority, randomised trial

Tailored Dose-Dense Versus Standard Adjuvant Chemotherapy for High-Risk Early Breast Cancer: End-of-Study Results of the Randomized PANTHER Trial

Long-term outcome of chemoimmunotherapy for extensive-stage small-cell lung cancer according to key clinical trial eligibility: 3-year outcomes from a prospective cohort study

Endocrine therapy and risk of cardiovascular disease and mortality in postmenopausal breast cancer survivors

Real-world treatment patterns and outcomes based on RAS/BRAF status in metastatic colorectal cancer-Analysis of the Prospective Dutch Colorectal Cancer cohort

Factors influencing 5-year persistence to adjuvant endocrine therapy in young women with breast cancer